Bio-Path (NASDAQ:BPTH – Get Free Report) announced its quarterly earnings results on Wednesday. The company reported ($1.16) EPS for the quarter, beating the consensus estimate of ($1.54) by $0.38, Yahoo Finance reports. During the same period last year, the business posted ($10.60) earnings per share.
Bio-Path Stock Performance
NASDAQ:BPTH traded down $0.03 on Friday, hitting $1.46. 17,659 shares of the stock were exchanged, compared to its average volume of 1,021,491. Bio-Path has a 52 week low of $1.31 and a 52 week high of $21.60. The company’s 50-day moving average price is $1.84 and its 200 day moving average price is $3.72.
Wall Street Analyst Weigh In
Several research analysts have recently commented on the company. StockNews.com began coverage on Bio-Path in a report on Thursday, May 2nd. They issued a “sell” rating on the stock. Roth Mkm reaffirmed a “buy” rating and set a $20.00 price objective on shares of Bio-Path in a report on Monday, July 8th.
About Bio-Path
Bio-Path Holdings, Inc operates as a clinical and preclinical stage oncology focused RNAi nanoparticle drug development company in the United States. The company develops products based on DNAbilize, a drug delivery and antisense technology platform that uses P-ethoxy, which is a deoxyribonucleic acid (DNA) backbone modification intended to protect the DNA from destruction.
Featured Articles
- Five stocks we like better than Bio-Path
- How to Find Undervalued Stocks
- JD.com Earnings Surprise: China’s Outlook Better Than Expected
- What Are Dividend Achievers? An Introduction
- Warren Buffett’s Recent Stock Moves: Top Buys and Sells to Watch
- Are Penny Stocks a Good Fit for Your Portfolio?
- Sea Limited’s E-Commerce and Fintech Strength Fuel Stock Surge
Receive News & Ratings for Bio-Path Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Bio-Path and related companies with MarketBeat.com's FREE daily email newsletter.
